Knowledge, attitude, and practice of board-certified dermatologists in Shiraz, Iran toward melasma management and their adherence to the recent dermatology guidelines
Keywords:
Melasma, Treatment, Knowledge, attitude, and practice (KAP), Dermatology guidelines, HydroquinoneAbstract
Background and aim of the work: Melasma is a common hyperpigmentation skin disorder that is more prevalent in females. Due to the negative effect of melasma on self-esteem and quality of life, early diagnosis and management would be essential. Although numerous therapeutic regimens have been considered, melasma treatment is still challenging and the desired clinical response cannot be achieved in some patients.
Research design and Methods: In this knowledge, attitude, and practice (KAP) survey, the point of views, approaches, and concepts of board-certified dermatologists toward melasma treatment were assessed. This KAP survey was performed through a standard questionnaire containing 9 questions which were distributed among the board-certified dermatologists who were practicing in various dermatology clinics or hospital wards of Shiraz, Iran. The obtained results were compared with the recommendations of various recent updated dermatology guidelines.
Results: The results revealed that dermatologists’ perspectives and attitudes toward melasma management showed good adherence to the recommendations of the dermatology guidelines. About 78% of dermatologists recommended topical preparations as the preferred route of administration for melasma management and about 80% of them recommended topical hydroquinone as the first-line treatment.
Conclusions: Although hydroquinone-containing topical formulations are efficient depigmenting agents for melasma treatment, concerns regarding their adverse drug reactions, especially in prolonged administration, still remained and demands are growing for the design and development of novel formulations and more efficacious delivery systems to reduce the adverse drug reactions of currently used medications and also to enhance therapeutic outcomes.
References
1. Böhm M. Disorders of Melanin Pigmentation. Braun-Falco´ s Dermatology: Springer,Berlin, Heidelberg; 2021. p. 1-35. doi:10.1007/978-3-642-97931-6_26
2. MELASMA: OVERVIEW [Available from: https://www.aad.org/public/diseases/a-z/melasma-overview.]
3. Jiang J, Akinseye O, Tovar-Garza A, Pandya A. The effect of melasma on self-esteem: A pilot study. Int J Womens Dermatol. 2018;4(1):38-42. doi:10.1016/j.ijwd.2017.11.003
4. Zhu Y, Zeng X, Ying J, Cai Y, Qiu Y, Xiang W. Evaluating the quality of life among melasma patients using the MELASQoL scale: A systematic review and meta-analysis. PLoS One. 2022;17(1):e0262833. doi:10.1371/journal.pone.0262833
5. Lee JD, Lee JK, Oh MJM, Lee JD, Lee JK, Oh MJM. Etiology and treatments of melasma. Principles and Choice of Laser Treatment in Dermatology: With Special Reference to the Asian Population. 2020:263-306. doi: 10.1007/978-981-15-6556-4
6. Suryaningsih BE, Sadewa AH, Wirohadidjojo YW, Soebono H. Association between heterozygote Val92Met MC1R gene polymorphisms with incidence of melasma: a study of Javanese women population in Yogyakarta. Clin Cosmet Investig Dermatol. 2019:489-95. doi:10.2147/CCID.S206115
7. Ghasemiyeh P, Fazlinejad R, Kiafar MR, Rasekh S, Mokhtarzadegan M, Mohammadi-Samani S. Different therapeutic approaches in melasma: advances and limitations. Front Pharmacol. 2024;15:1337282. doi:10.3389/fphar.2024.1337282
8. Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatol Ther . 2017;7:305-18. doi:10.1007/s13555-017-0194-1
9. MELASMA: CAUSES [Available from: https://www.aad.org/public/diseases/a-z/melasma-causes.]
10. MELASMA: DIAGNOSIS AND TREATMENT [Available from: https://www.aad.org/public/diseases/a-z/melasma-treatment.]
11. TRI-LUMA Cream [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021112s009lbl.pdf.]
12. Desai SR, Alexis AF, Elbuluk N, et al. Best practices in the treatment of melasma with a focus on patients with skin of color. J Am Acad Dermatol. 2024;90(2):269-79. doi:10.1016/j.jaad.2023.07.1045
13. AlSalem S, Alexis A. Melasma hyperpigmentation: An overview of current topical therapeutics. Dermatological Reviews. 2023;4(1):38-52. doi:10.1002/der2.152
14. Melasma [Available from: https://www.dermcoll.edu.au/wp-content/uploads/2021/05/Melasma-Skin-A-Z-of-Skin.pdf.]
15. Ko D, Wang RF, Ozog D, Lim HW, Mohammad TF. Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation. J Am Acad Dermatol. 2023;88(2):291-320. doi: 10.1016/j.jaad.2021.12.065
16. Moolla S, Miller-Monthrope Y. Dermatology: how to manage facial hyperpigmentation in skin of colour. Drugs Context. 2022;11. doi:10.7573/dic.2021-11-2
17. Doolan BJ, Gupta M. Melasma. Aust J Gen Pract. 2021;50(12):880-5. doi:10.31128/AJGP-05-21-6002
18. Goel A, Trivedi N. Current updates on melasma treatments. Cosmoderma. 2023;3. doi:10.25259/CSDM_84_2023
19. Torok HM. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. Am J Clin Dermatol. 2006;7:223-30. doi:10.2165/00128071-200607040-00003
20. Tangau MJ, Chong YK, Yeong KY. Advances in cosmeceutical nanotechnology for hyperpigmentation treatment. J Nanoparticle Res. 2022;24(8):155. doi:10.1007/s11051-022-05534-z
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Parisa Ghasemiyeh, Soliman Mohammadi-Samani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
